SCHEMBL83759

SCHEMBL83759

CCOC(=O)CC(NCc1ccccc1)C(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPID Q08752 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 3/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 4/20 0.43
MMP8 P22894 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
EPHX2 P34913 1/20 0.41
PPARG P37231 1/20 0.41
ALOX5 P09917 1/20 0.40
NAMPT P43490 1/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
GAA P10253 1/20 0.40
APEX1 P27695 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4849475 0.87 PPID (0.52) PPIDSMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL11241912 0.85 PPID (0.50) PPIDSMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL17189484 0.83 SMN1; SMN2 (0.40) PPIDSMN1; SMN2MAPTMMP8MEN1
SCHEMBL8936169 0.81 PPID (0.55) PPIDSMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL536970 0.81 PPID (0.55) PPIDSMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL30305384 0.80 ALDH1A1 (0.46) PPIDSMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL911372 0.80 PPID (0.54) PPIDSMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL16079372 0.80 PPID (0.54) PPIDSMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL9554766 0.80 PPID (0.54) PPIDSMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL4851565 0.80 PPID (0.54) PPIDSMN1; SMN2ALDH1A1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116354932-A Pyrimidine derivative, preparation method and application thereof 海思科医药集团股份有限公司 2023-06-30 CN disclosed
EP-2091926-B1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2015-10-21 EP disclosed
US-8129358-B2 Substituted pyrazole and triazole compounds as KSP inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129358-B2 Substituted pyrazole and triazole compounds as KSP inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
US-7902240-B2 Kinesin spindle protein (KSP); anticancer agents; antiproliferative agents; e.g. N-((S)-3-amino-4-fluorobutyl)-N ((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)nicotinamide NOVARTIS AG (CH) 2011-03-08 US disclosed
US-7902240-B2 Kinesin spindle protein (KSP); anticancer agents; antiproliferative agents; e.g. N-((S)-3-amino-4-fluorobutyl)-N ((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)nicotinamide NOVARTIS AG (CH) 2011-03-08 US disclosed
US-20100034813-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2010-02-11 US disclosed
US-20100034813-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2010-02-11 US disclosed
US-20080200462-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG 2008-08-21 US disclosed
US-20080200462-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG 2008-08-21 US disclosed
WO-2008063912-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2008-05-29 WO disclosed
EP-0046712-B1 FLUORINATED DIAMINOBUTANE DERIVATIVES MERRELL TORAUDE ET COMPAGNIE (FR) 1985-02-06 EP disclosed
US-4435425-A INHIBITORS OF GAMMA-AMINOBUTYRIC ACID TRANSAMINASE MERRELL TORAUDE ET COMPAGNIE (FR) 1984-03-06 US disclosed
EP-0046712-A1 Fluorinated diaminobutane derivatives MERRELL TORAUDE ET COMPAGNIE (FR) 1982-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100034813-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS CYP3A43, ABCG2, CYP3A7 PPID 1539/4885SMN1; SMN2 4528/4885ALDH1A1 1512/4885
US-20080200462-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS CYP3A43, ABCG2, CYP3A7 PPID 1539/4885SMN1; SMN2 4528/4885ALDH1A1 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.